secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001193125-24-283008
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion icovamenib Phase II meets primary endpoint; 1.47% HbA1c reduction in insulin-deficient T2D patients
--------------------------------------------------------------------------------

- Best response in beta-cell deficient patients on antidiabetic agents: placebo-adjusted HbA1c reduction 1.47% at Week 26 (p=0.022) after 12 weeks dosing.
- Arm B (100mg QD for 12 weeks) showed mean HbA1c reduction of 0.5% (p=0.012) in per protocol patients on one or more baseline therapy.
- In insulin-deficient subtypes (SIDD/MARD), Arm B demonstrated mean HbA1c reduction of 1.05% (p=0.004).
- Icovamenib well-tolerated: no AE-related discontinuations, no hypoglycemic events, no related serious adverse events.
- Company plans to discuss data with FDA; 52-week readout anticipated in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/0001193125-24-283008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/d827448d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-283008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer